The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

Genentech's ranibizumab injection (Susvimo) has received FDA approval for the treatment of diabetic retinopathy. The ...

The approval is based on positive 1-year data from the phase 3 Pavilion study. This is Susvimo’s third FDA-approved indication. Perspective from David A. Eichenbaum, MD The FDA approved Susvimo ...

The ranibizumab ocular implant (Susvimo) reduces the need for frequent intravitreal anti-VEGF injections in patients with neovascular age-related macular degeneration or diabetic macular edema, and ...

Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ...

Susvimo can help DR patients maintain their vision and prevent progression to blindness with only one treatment every nine months. Year to date, shares of Roche have risen 14.4% against the ...

Credit: Genentech. Susvimo is indicated for intravitreal use via the Susvimo ocular implant. For patients with diabetic retinopathy, refills of Susvimo are administered every 36 weeks ...

Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine months – – Susvimo’s innovative ...

Approval of Susvimo marks the first continuous delivery therapy indicated for diabetic retinopathy. The FDA has approved Roche’s Susvimo (ranibizumab injection) 100 mg/mL for treating patients with ...